Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

161. Spiolto Respimat (tiotropium/olodaterol) - chronic obstructive pulmonary disease (COPD)

patients with chronic obstructive pulmonary disease (COPD). The LAMA component, tiotropium (Spiriva®), and the LABA component, olodaterol (Striverdi®), each have the same indication as Spiolto Respimat®. Despite statistically significant differences in several patient-specific measures of effectiveness (e.g. quality of life) favouring Spiolto Respimat® over the individual components, the efficacy is assessed to have limited clinical relevance in patients not yet started on relevant symptom-alleviating (...) Spiolto Respimat (tiotropium/olodaterol) - chronic obstructive pulmonary disease (COPD) Spiolto Respimat® (tiotropium/olodaterol) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Spiolto Respimat® (tiotropium/olodaterol) Conclusion Spiolto Respimat® (tiotropium/olodaterol) combines a long-acting muscarinic antagonist (LAMA) with a long-acting beta agonist (LABA) and is approved for maintenance bronchodilator treatment to relieve symptoms in adult

2017 Danish Pharmacotherapy Reviews

162. Incruse (umeclidinium) - chronic obstructive pulmonary disease

Incruse (umeclidinium) - chronic obstructive pulmonary disease Incruse® (umeclidinium) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Incruse® (umeclidinium) Conclusion Incruse® is a new inhalation product of the type of long-acting muscarinic antagonists (LAMA) approved for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The treatment is given once daily, and the registered dose is 55 micrograms (µg (...) , Karabis A. Int J Chron Obstruct Pulmon Dis. 2015 Nov 16;10:2495-517. 3. IRF’s præparatanmeldelser af Anoro, 28/1-2015: 4. IRF’s præparatanmeldelser af Relvar, 11/7-2014: 5. Tiotropium versus placebo for chronic obstructive pulmonary disease. Karner C, Chong J, Poole P.Cochrane Database Syst Rev. 2014 Jul 21;7:CD009285. 23 August 2016 The Danish Health Authority Islands Brygge 67 2300 København S Denmark Telephone: +45 72 22 74 00

2017 Danish Pharmacotherapy Reviews

163. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease Full Text available with Trip Pro

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in patients with COPD.The FULFIL (Lung Function and Quality of Life (...) Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) trial was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 μg/12 μg; Turbuhaler). A patient subgroup remained on blinded treatment for up to 52 weeks. Co-primary endpoints were change from baseline in trough FEV1 and in St. George's

2017 EvidenceUpdates

164. Patient experience of lung volume reduction procedures for emphysema: a qualitative service improvement project Full Text available with Trip Pro

Patient experience of lung volume reduction procedures for emphysema: a qualitative service improvement project The aim of this service improvement project was to gain understanding of the patient experience of lung volume reduction surgery (LVRS) and endobronchial valve (EBV) placement, from referral through to post-discharge care. Focus group interviews were carried out in two tertiary centres in London and Leicester, UK. Sixteen patients who had undergone lung volume reduction surgery (LVRS (...) ), endobronchial valve (EBV) placement, or both, were recruited. Prior to participation in each focus group, participants completed a questionnaire to guide and focus discussion. Thematic analysis identified common themes to the participant experience of receiving lung volume reduction interventions. Themes included patient focus on declining health and the need to "fight" for a referral; consequences of having procedures and potential unexpected complications; and vulnerability post discharge and limited

2017 ERJ open research

165. Perceptıon scale of barrıers to contraceptıve use: a methodologıcal study Full Text available with Trip Pro

Perceptıon scale of barrıers to contraceptıve use: a methodologıcal study The objective of this study was to design and develop the Perception Scale of Barriers to Contraceptive Use (PSBCU) as a measurement tool for the qualitative assessment of the barriers and obstacles women perceived with regard to contraceptive use or low rates of contraceptive use in women using family planning services.The data for this methodological study were collected using the face-to-face interview technique

2017 Fertility research and practice

166. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits Full Text available with Trip Pro

Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits Pulmonary rehabilitation (PR) remains grossly underutilised by suitable patients worldwide. We investigated whether home-based maintenance tele-rehabilitation will be as effective as hospital-based maintenance rehabilitation and superior to usual care in reducing the risk for acute chronic obstructive pulmonary disease (COPD) exacerbations (...) and hospital-based PR remained independent predictors of a lower risk for 1) acute COPD exacerbation (incidence rate ratio (IRR) 0.517, 95% CI 0.389-0.687, and IRR 0.635, 95% CI 0.473-0.853), respectively, and 2) hospitalisations for acute COPD exacerbation (IRR 0.189, 95% CI 0.100-0.358, and IRR 0.375, 95% CI 0.207-0.681), respectively. However, only home-based maintenance tele-rehabilitation and not hospital-based, outpatient, maintenance PR was an independent predictor of ED visits (IRR 0.116, 95% CI

2017 EvidenceUpdates

167. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Full Text available with Trip Pro

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD.We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002-2012, from the UK Clinical Practice (...) , was not associated with an increased risk of AMI (hazard ratio (HR) 1.12, 95% CI 0.92-1.36), stroke (HR 0.87, 95% CI 0.69-1.10) or arrhythmia (HR 1.05, 95% CI 0.81-1.36), but the risk was elevated for heart failure (HR 1.16, 95% CI 1.03-1.30).Adding a second long-acting bronchodilator in the real-world-setting treatment of COPD does not increase the risk of most cardiovascular events. The modest increase for heart failure warrants further investigation.Copyright ©ERS 2017.

2017 EvidenceUpdates

168. Trimbow (beclometasone / formoterol / glycopyrronium bromide) - chronic obstructive pulmonary disease (COPD)

applied for the following indication: Trimbow is indicated for the symptomatic treatment and reduction of exacerbations in adult patients with chronic obstructive pulmonary disease (COPD) with airflow limitation (FEV 1 0.01 threshold (N) Substance (INN/Invented Name): glycopyrronium bromide CAS-number (if available): 51186-83-5 PBT screening Result Conclusion Bioaccumulation potential- log K ow OECD 107 -1.35 Potential PBT (N) PBT-assessment Parameter Result relevant for conclusion Conclusion (...) Trimbow (beclometasone / formoterol / glycopyrronium bromide) - chronic obstructive pulmonary disease (COPD) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 18 May 2017 EMA/CHMP/289952/2017 Committee for Medicinal Products

2017 European Medicines Agency - EPARs

169. Targeted lung denervation by catheter ablation in chronic obstructive lung disease - Assessments according to §137h SGB V

) to assess targeted lung denervation (TLD) using catheter ablation for chronic obstructive pulmonary disease (COPD) according to §137h Social Code Book (SGB) V – Statutory Health Insurance. The assessment documents were transferred to IQWiG on 19 December 2016. According to the requesting hospital, TLD aims to avoid airway obstruction in patients with COPD by a permanent interception of parasympathetic nerve fibres in the area of both main bronchi, and thereby in particular to improve respiratory (...) is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. H16-01 Targeted lung denervation using catheter ablation for chronic obstructive pulmonary disease 1 Executive summary of assessment H16-01 according to §137h SGB V Version 1.0 Targeted lung denervation for COPD 30 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Targeted lung denervation using

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

170. Roflumilast for treating chronic obstructive pulmonary disease

by obstruction of the airways, breathlessness and cough. Airflow limitation becomes worse over time, with periodic acute exacerbations. The clinical expert advised that despite treatment with optimal inhaled therapy many people with severe COPD have several exacerbations each year, which is a huge burden on patients and the NHS. Exacerbations worsen a patient's health status, reduce their quality of life, accelerate decline in lung function, lead to hospitalisation and increase mortality. The committee (...) Evidence 6 4 Committee discussion 7 Clinical need of people with COPD 7 Clinical management of COPD 7 Comparators 8 Clinical effectiveness 8 Cost effectiveness 10 Pharmaceutical Price Regulation Scheme 2014 13 Summary of appraisal committee's key conclusions 13 5 Implementation 19 6 Appraisal committee members and NICE project team 20 Appraisal committee members 20 NICE project team 20 Roflumilast for treating chronic obstructive pulmonary disease (TA461) © NICE 2018. All rights reserved. Subject

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

171. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis Full Text available with Trip Pro

Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10-70 years with a history of drug-susceptible (DS)- or multidrug-resistant (...) capacity -370 mL, 95% CI -644- -97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27-18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio <0.70 (adjusted OR 2.47, 95% CI 1.01-6.03). Individuals successfully treated for TB may experience long-lasting sequelae. Interventions facilitating earlier TB treatment and management

2017 ERJ open research

172. Impact of pulmonary rehabilitation on postoperative complications in patients with lung cancer and chronic obstructive pulmonary disease Full Text available with Trip Pro

lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD).The records of 116 patients with COPD, including 51 patients who received PR, were retrospectively analyzed. Pulmonary function testing, including slow vital capacity (VC) and forced expiratory volume in one second (FEV1 ), was obtained preoperatively, after PR, and at one and six months postoperatively. The recovery rate of postoperative pulmonary function was standardized for functional loss associated (...) Impact of pulmonary rehabilitation on postoperative complications in patients with lung cancer and chronic obstructive pulmonary disease Given the extent of the surgical indications for pulmonary lobectomy in breathless patients, preoperative care and evaluation of pulmonary function are increasingly necessary. The aim of this study was to assess the contribution of preoperative pulmonary rehabilitation (PR) for reducing the incidence of postoperative pulmonary complications in non-small cell

2017 Thoracic cancer

173. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD Full Text available with Trip Pro

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease.For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium (...) /olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler. Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75% of peak incremental work rate after 6 weeks (2 h post-dose).295 and 291 patients were treated in MORACTO 1 and 2, respectively. Tiotropium/olodaterol 2.5/5 and 5/5 µg provided significant improvements in inspiratory capacity versus placebo

2017 EvidenceUpdates

174. [Procedure for lung volume reduction in severe lung emphysema]

publication URL Indexing Status Subject indexing assigned by CRD MeSH Emphysema; Humans; Lung; Pneumonectomy; Pulmonary Emphysema Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000266 Date abstract record published 13/06/2017 Health Technology (...) [Procedure for lung volume reduction in severe lung emphysema] Verfahren zur lungenvolumenreduktion beim schweren lungenemphysem: abschlussbericht; auftrag N14-04 [Procedure for lung volume reduction in severe lung emphysema] Verfahren zur lungenvolumenreduktion beim schweren lungenemphysem: abschlussbericht; auftrag N14-04 [Procedure for lung volume reduction in severe lung emphysema] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record

2017 Health Technology Assessment (HTA) Database.

175. Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines

the use of colistin for the prophylactic treatment of adults with either non-CF bronchiectasis or patients with COPD experiencing exacerbations. Tags copd, infection control, bronchiectasis, colistin, pulmonary disease, chronic obstructive, pulmonary emphysema, respiratory, colistimethate sodium, polymyxin E, Colisticin, chronic airflow obstruction, Chronic obstructive airway disease, Chronic obstructive lung disease, Chronic obstructive pulmonary disease, chronic bronchitis, emphysema, colomycin (...) pulmonary disease experiencing exacerbations? What is the cost-effectiveness of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients with chronic obstructive pulmonary disease experiencing exacerbations? What are the evidence-based guidelines associated with the use of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients with chronic obstructive pulmonary disease experiencing exacerbations

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

176. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Full Text available with Trip Pro

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long-acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long-acting muscarinic antagonists approved (...) for treatment of patients with stable COPD.To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.We included randomised controlled trials (RCTs

2017 Cochrane

177. Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data Full Text available with Trip Pro

Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data It is often difficult to determine the cause of chronic obstructive pulmonary disease (COPD) exacerbations, and antibiotics are frequently prescribed. This study conducted an observational cost-effectiveness analysis of prescribing antibiotics for exacerbations of COPD based on routinely collected data from patient electronic health records. A cohort of 45 375 patients aged 40 years or more who (...) in the base case. The use of antibiotics for COPD exacerbations resulted in cost savings and an improvement in all outcomes analysed; i.e. GP visits, hospitalisations, community respiratory team referrals, all referrals, infections and subsequent antibiotics prescriptions were lower for the antibiotics group. Hence, the use of antibiotics was dominant over no antibiotics. The economic analysis suggests that use of antibiotics for COPD exacerbations is a cost-effective alternative to not prescribing

2017 ERJ open research

178. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Full Text available with Trip Pro

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers with COPD.To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD.In a retrospective cohort study, we used data from 14 350 patients with COPD included (...) in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350) or varenicline (N=3574) in the period between January 2007 and June 2012. Patients were followed up for 6 months to compare incident cardiovascular (ie, ischaemic heart disease, stroke, heart failure, peripheral vascular disease and cardiac arrhythmias

2017 EvidenceUpdates

179. Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease. Full Text available with Trip Pro

Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction due to an abnormal inflammatory response of the lungs to noxious particles or gases, for example, cigarette smoke. The pattern of care for people with moderate to very severe COPD often involves regular lengthy hospital admissions, which result in high healthcare costs and an undesirable effect on quality (...) function, or anxiety and depression.All three studies included our primary outcome - health-related quality of life (HRQoL) as measured by the Clinical COPD Questionnaire (CCQ) or St George's Respiratory Questionnaire (SGRQ). One study reported our other primary outcomes - hospital admissions and acute exacerbations. Two studies included our secondary outcome of physical activity as measured by daily step counts. One study addressed smoking by providing a narrative analysis. Only one study reported

2017 Cochrane

180. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death.To investigate the effect of home NIV plus oxygen on time to readmission or death in patients with persistent (...) hypercapnia after an acute COPD exacerbation.A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible.There were 59 patients randomized to home oxygen alone (median oxygen

2017 JAMA Controlled trial quality: predicted high